Orion Corporation

Ilkka Larma

Raimo E Virtanen

Lasse Lehtonen

Martti Marvola

Kauko Kurkela

Saila Antila

Maarit B&auml;ckman

Marianne Karlsson

The present invention relates to pharmaceutical compositions of levosimendan comprising alginic acid for improving the stability of levosimendan in the compositions. Levosimendan is useful in the treatment of congestive heart failure.

Stable compositions comprising levosimendan and alginic acid

A method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.

Transmucosal formulations of levosimendan

A composition for oral administration comprising a substantially pure crystalline polymorphic form (I) of levosimendan as an active ingredient together with a pharmaceutically acceptable carrier is described. Polymorphic form (I) of levosimendan is rapidly absorbed from the gastrointestinal tract and is useful in the treatment of congestive heart disease.

Oral compositions of levosimendan

Growing community of inventors

Springfield, NJ, United States of America

Ilkka Larma